Tekla Capital Management

Total investments

51

Average round size

66M

Portfolio companies

41

Rounds per year

1.34

Lead investments

5

Follow on index

0.20

Exits

18

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalDeveloper PlatformLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

The main office of represented VC is situated in the Boston. The company was established in North America in United States.

We also calculated 1 valuable employee in our database.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Tekla Capital Management, startups are often financed by Novartis Venture Fund, Domain Associates, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Sofinnova Investments, Redmile Group. In the next rounds fund is usually obtained by Sofinnova Investments, Life Sciences Partners, Ysios Capital.

The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 3 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. This Tekla Capital Management works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018.

Among the most popular portfolio startups of the fund, we may highlight Afferent Pharmaceuticals, Merus, CuraSen Therapeutics. We can highlight the next thriving fund investment areas, such as Medical, Health Care. The fund has exact preference in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Show more

Investments analytics

Analytics

Total investments
51
Lead investments
5
Exits
18
Rounds per year
1.34
Follow on index
0.20
Investments by industry
  • Biotechnology (46)
  • Health Care (29)
  • Therapeutics (23)
  • Medical (18)
  • Pharmaceutical (14)
  • Show 16 more
Investments by region
  • United States (37)
  • Switzerland (4)
  • France (2)
  • Iceland (3)
  • United Kingdom (1)
  • Show 3 more
Peak activity year
2021
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
68M
Group Appearance index
1.00
Avg. company exit year
14
Avg. multiplicator
4.79
Strategy success index
0.60

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Endeavor BioMedicines 24 Apr 2024 Biotechnology Late Stage Venture 132M United States, California
Parthenon Therapeutics 03 Nov 2021 Biotechnology, Life Science, Therapeutics Early Stage Venture 65M United States, Massachusetts, Cambridge

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.